Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Aprotinin in Moderate or Severe ARDS
NCT07317050Phase 3Recruiting
- Start
- Jun 2026
- Primary completion
- Mar 2030
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of aprotinin in acute respiratory distress syndrome (ARDS). Started Jun 2026; status: recruiting.
02
Drugs
aprotinin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07317050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317050.